BridgeBio Pharma, Inc.

NASDAQ:BBIO

Biotechnology

Healthcare
$78.01 +1.13%

+$0.75 today

Market cap
$15.20B
Beta
0.97
P/E (TTM)
-18.1
EPS (TTM)
-$3.73
52W Low $40.19High $84.94

Volume 3.55M

Average 2.49M

BBIO Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

BridgeBio Pharma, Inc.NASDAQ: BBIO

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables growth accelerates

Q2 FY2026 accounts payables of $1.86M (cash outflow) rose 75.9% year over year, ahead of the -88.4% change in trailing-twelve-month accounts payables. Sequentially, it fell 74.1% from the prior quarter.

Context

  • Accounts payables amounted to 5.3% of revenue in FY2025, up 4.6 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +75.9% holds above the trailing-twelve-month pace of -88.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$1.86M-74.1% QoQ
Last fiscal yearDec 2025
$26.61M+1659.9% YoY
LTMJun 2026
$1.07M-88.4% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+75.9%——
1 year+1659.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
26.61M USD
Year-over-year change
+1659.9%
4-year CAGR
+75.1%

Accounts Payables vs competitors

How BBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -88.4% is the 6th highest of 9, against a peer median of -29.4%.
  • Accounts payables amounts to 0.1% of revenue for BBIO, versus a peer median of 3.6%.
BBIO Competitors
Accounts Payables for BBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$52.73B USD-274455.3%+3.9%5.1%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$65.76M USD-237.3%-26.8%1.4%
ASNDAscendis Pharma A/SLTM Sep 2026€58.15M EUR——4.8%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$15.45M USD+166.8%-33.0%2.3%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$11.71M USD-66.8%—1.2%
DNLIDenali Therapeutics Inc.LTM Jun 2026$3.38M USD+7.9%—93.6%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$2.72M USD+151.1%—0.4%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$1.61M USD+159.9%-80.7%8.0%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$1.07M USD-88.4%—0.1%
SRRKScholar Rock Holding CorporationLTM Sep 2026$599K USD-122.2%—105.1%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding BBIO) —-29.4%-29.9%3.6%

Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(586.45M)(484.65M)(643.2M)(543.35M)(724.93M)
Depreciation & Amortization5.84M6.77M6.49M6.08M5.43M
Deferred Income Tax(30.93M)0000
Stock-Based Compensation99.51M91.56M095.8M133.02M
Change in Working Capital(4.4M)28.08M5.06M32.04M(51.06M)
Accounts Receivables(19.75M)15.17M15.33M(2.97M)(134.72M)
Inventory19.75M000(25.31M)
Accounts Payables2.83M(349K)2.78M1.51M26.61M
Other Working Capital(7.23M)13.26M(13.05M)33.5M82.36M
Other Non-Cash Items18.5M(61.25M)103.93M(111.3M)191.63M
Operating Cash Flow(497.93M)(419.49M)(527.72M)(520.73M)(445.91M)
Capital Expenditures(48.25M)(6.32M)(1.31M)(933K)(1.1M)
Acquisitions (Net)(35M)00(140K)0
Purchases of Investments(643.28M)(193.06M)(137.26M)(88.4M)(28.2M)
Sales of Investments477.04M532.52M193.11M158.23M11M
Other Investing Activities48.65M118.5M(503K)(7.98M)(6.19M)
Investing Cash Flow(200.83M)453.15M54.03M60.78M(24.49M)
Debt Repayment1.08B(20.49M)0476.58M385.5M
Common Stock Issued04.85M449.81M314.74M34.15M
Common Stock Repurchased(204.75M)(1.56M)(6.88M)(7.53M)(48.28M)
Dividends Paid00000
Other Financing Activities(138.49M)4.06M8.61M(35.34M)(12.08M)
Financing Cash Flow736.45M(13.13M)451.54M748.46M359.29M
Effect of Forex Changes00000
Net Change in Cash37.69M20.52M(22.15M)288.51M(111.1M)
Free Cash Flow(546.18M)(425.82M)(529.03M)(521.66M)(447.01M)

BridgeBio Pharma, Inc.

NASDAQ:BBIO

Intrinsic Alpha fair value

Locked

Current Price

$78.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.